Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tafoxiparin - Dilafor

Next Previous
Drug Profile

Tafoxiparin - Dilafor

Alternative Names: DF-01; Tafoxiparin-Dilafor; Tafoxiparin-sodium

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dilafor
  • Developer Dilafor; Lee's Pharmaceutical; University of Liverpool
  • Class Antivirals; Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Muscle protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dystocia; Preeclampsia
  • No development reported COVID 2019 infections

Most Recent Events

  • 16 Jun 2025 Dilafor plans a phase I bioequivalence trial (In volunteers) in Sweden (SC) (CTIS2025-521140-38-00) (EudraCT2025521140-38-00)
  • 30 Jan 2025 Dilafor completed meetings with USFDA and European Health Agencies regarding development of Tafoxiparin
  • 30 Jan 2025 Dilafor plans a phase III trial for Priming of labour in Europe

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top